Efficacy of an acellular pertussis vaccine among adolescents and adults.

@article{Ward2005EfficacyOA,
  title={Efficacy of an acellular pertussis vaccine among adolescents and adults.},
  author={Joel Ward and James D. Cherry and Swei-Ju Chang and Susan Partridge and Hang Lee and John J. Treanor and David P. Greenberg and Wendy A Keitel and Stephen J. Barenkamp and David I Bernstein and Robert R. Edelman and Kathryn M. Edwards},
  journal={The New England journal of medicine},
  year={2005},
  volume={353 15},
  pages={
          1555-63
        }
}
BACKGROUND Pertussis immunization of adults may be necessary to improve the control of a rising burden of disease and infection. This trial of an acellular pertussis vaccine among adolescents and adults evaluated the incidence of pertussis, vaccine safety, immunogenicity, and protective efficacy. METHODS Bordetella pertussis infections and illnesses were prospectively assessed in 2781 healthy subjects between the ages of 15 and 65 years who were enrolled in a national multicenter, randomized… 

Tables from this paper

Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT).

  • J. WardJ. Cherry R. Edelman
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2006
TLDR
A multicenter, randomized, double-blind vaccine trial in which one-half of the subjects received aP vaccine and one- half received hepatitis A vaccine, finding that aP boosters confer protection for adolescents and adults against symptomatic pertussis and likely confer protection against mild and asymptomatic infections.

Acellular pertussis vaccine for adolescents.

TLDR
The literature indicates the possibility of solving the "reappearance" of whooping cough (pertussis) with the use of Tdap vaccine, and the strategy of using a second booster dose in adolescence to replace the double diphtheria and tetanus vaccine should be adopted immediately.

Acellular pertussis vaccine for adolescents.

TLDR
The literature indicates the possibility of solving the "reappearance" of whooping cough (pertussis) with the use of Tdap vaccine, and the strategy of using a second booster dose in adolescence to replace the double diphtheria and tetanus vaccine should be adopted immediately.

Boostrix™: a reduced-dose acellular pertussis vaccine for use in adolescents and adults

TLDR
Boostrix™ is a reduced-dose acellular pertussis vaccine with diphtheria and tetanus toxoids, and is designed for use in adolescents and adults, and current evidence suggests that Boostrix is immunogenic and well tolerated.

Acellular Pertussis Vaccine Booster Combined With Diphtheria and Tetanus Toxoids for Adolescents

TLDR
In adolescents, the studied Tdap was safe and immunogenic and induced pertussis antibodies that were higher than those associated with efficacy in infants.

Pertussis immunisation in adolescents and adults – Bordetella pertussis epidemiology should guide vaccination recommendations

TLDR
The authors believe that the morbidity of pertussis and its spread to infants can be dramatically reduced, and it is possible that the circulation of B. pertussedis could be eliminated.

Pertussis infection in the United States: role for vaccination of adolescents and adults.

TLDR
The CDC's Advisory Committee on Immunization Practices (ACIP) revised its recommendations for pertussis vaccination to include a Tdap booster dose for all adolescents aged 11 to 12 years as well as catch-up vaccination of those aged 13 to 18 years who did not receive the Td booster.

Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak.

  • M. WittPaul H. KatzD. Witt
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2012
TLDR
The data suggests that the current schedule of acellular pertussis vaccine doses is insufficient to prevent outbreaks of pertussIS, and the possibility of earlier or more numerous booster doses of a cellular pertussedis vaccine either as part of routine immunization or for outbreak control should be entertained.

Immunization against pertussis in adolescents and adults.

  • S. EspositoN. Principi
  • Medicine, Biology
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2016

Decreasing childhood pertussis infection through vaccination of the elderly.

TLDR
Evidence exists of waning immunity in the adult population after either infection or vaccination, and a recommendation for the use of a pertussis-containing vaccine (Tdap) in persons 64 years of age and older would be of considerable benefit to the public in preventing some transmission of pertussi to children.
...

References

SHOWING 1-10 OF 34 REFERENCES

Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis.

TLDR
Of these strategies, the most economical would be to immunize adolescents 10-19 years of age, which would prevent 0.7-1.8 million pertussis cases and save 0.6 dollars- 1.6 billion dollars over a decade.

Acellular Pertussis Vaccine Booster Combined With Diphtheria and Tetanus Toxoids for Adolescents

TLDR
In adolescents, the studied Tdap was safe and immunogenic and induced pertussis antibodies that were higher than those associated with efficacy in infants.

Epidemiological, clinical, and laboratory aspects of pertussis in adults.

  • J. Cherry
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1999
TLDR
It is believed that B. pertussis circulation cannot be controlled by the present childhood immunization program, and acellular pertussedis vaccines make adolescent and adult booster immunization programs possible, and these could lead to a decrease in the circulation of the organism.

A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization.

TLDR
The safety and immunogenicity of 5 acellular pertussis vaccines (ACVs) were compared in a multicenter, randomized, double-blind trial and data support evaluation of ACVs for broader use among adolescents and adults.

Clinical and laboratory diagnosis of pertussis in the regions of a large vaccine efficacy trial in Germany

As a support service for a pertussis vaccine efficacy trial, a central diagnostic laboratory was established. Physicians in the geographic areas of the planned study were encouraged to send

Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study.

TLDR
Findings support the use of ACP booster immunizations for adolescents and adults, to provide sustained levels of antibody, and suggest that geometric mean titers likely remain above the LOQ for 2-9 years and above the threshold of detection for 4-13 years.

Serologic response and antibody-titer decay in adults with pertussis.

  • U. HeiningerJ. CherryK. Stehr
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2004
TLDR
After reaching peak levels, titer of antibody to pertussis toxin decreased more than did titers of antibodies to filamentous hemagglutinin, pertactin, and fimbriae type 1 and type 2, and the antibody decay patterns are similar in both groups.

Pertussis Vaccines for Adolescents and Adults

TLDR
Both Adacel and Boostrix have similar reactogenicity profiles as adult-formulated diphtheria and tetanus toxoids and after a single dose, both vaccines elicit vigorous antibody responses to the antigens that they contain.

The Epidemiology of Pertussis: A Comparison of the Epidemiology of the Disease Pertussis With the Epidemiology of Bordetella pertussis Infection

TLDR
It is suggested that a universal program of adolescent and adult boosters would decrease the circulation of B pertussis in these age groups and possibly could lead to the elimination of the organism from the population.